A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for ...
CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
The coronavirus disease 2019 (COVID-19) pandemic was one of the most serious public health calamities in the last decade, causing global morbidity and mortality in the millions. The emergence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results